Pfizer raises pressure on GSK, J&J with late-stage RSV vacci...
Pfizer has vaulted ahead with its respiratory syncytial virus (RSV) vaccine, closing the gap with GlaxoSmithKline and Johnson & Johnson as the companies strive to bring the first licens